EP3620212A1 - Fermented violet extract, method for obtaining such an extract and use in cosmetics - Google Patents
Fermented violet extract, method for obtaining such an extract and use in cosmetics Download PDFInfo
- Publication number
- EP3620212A1 EP3620212A1 EP19195311.6A EP19195311A EP3620212A1 EP 3620212 A1 EP3620212 A1 EP 3620212A1 EP 19195311 A EP19195311 A EP 19195311A EP 3620212 A1 EP3620212 A1 EP 3620212A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- violet
- species
- fermented
- fermented extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 112
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000002537 cosmetic Substances 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 238000000855 fermentation Methods 0.000 claims abstract description 48
- 230000004151 fermentation Effects 0.000 claims abstract description 48
- 241000894006 Bacteria Species 0.000 claims abstract description 43
- 239000007788 liquid Substances 0.000 claims abstract description 29
- 238000011534 incubation Methods 0.000 claims abstract description 28
- 244000005700 microbiome Species 0.000 claims abstract description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 27
- 230000008569 process Effects 0.000 claims abstract description 23
- 241000894007 species Species 0.000 claims abstract description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000605 extraction Methods 0.000 claims abstract description 17
- 235000000346 sugar Nutrition 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000004310 lactic acid Substances 0.000 claims abstract description 9
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 8
- 239000008101 lactose Substances 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 244000172533 Viola sororia Species 0.000 claims description 54
- 241001509070 Viola alba subsp. dehnhardtii Species 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 10
- 206010000496 acne Diseases 0.000 claims description 10
- 210000004400 mucous membrane Anatomy 0.000 claims description 9
- 241000589220 Acetobacter Species 0.000 claims description 7
- 229920002488 Hemicellulose Polymers 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 241001509397 Viola alba Species 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 241000589236 Gluconobacter Species 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 208000032544 Cicatrix Diseases 0.000 claims description 3
- 241000235344 Saccharomycetaceae Species 0.000 claims description 3
- 241000235345 Schizosaccharomycetaceae Species 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 3
- 230000037387 scars Effects 0.000 claims description 3
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 238000010899 nucleation Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 36
- 210000003491 skin Anatomy 0.000 description 26
- 238000012360 testing method Methods 0.000 description 20
- 241000186427 Cutibacterium acnes Species 0.000 description 16
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 14
- 102000008186 Collagen Human genes 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 13
- 241000191940 Staphylococcus Species 0.000 description 13
- 229940055019 propionibacterium acne Drugs 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 8
- 241001106476 Violaceae Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000009759 skin aging Effects 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 241000235017 Zygosaccharomyces Species 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000018612 quorum sensing Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 241000589232 Gluconobacter oxydans Species 0.000 description 4
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 241000405217 Viola <butterfly> Species 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000032770 biofilm formation Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 235000012544 Viola sororia Nutrition 0.000 description 3
- 244000225942 Viola tricolor Species 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001468155 Lactobacillaceae Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 244000253911 Saccharomyces fragilis Species 0.000 description 2
- 241000235346 Schizosaccharomyces Species 0.000 description 2
- 240000009038 Viola odorata Species 0.000 description 2
- 235000013487 Viola odorata Nutrition 0.000 description 2
- 235000004031 Viola x wittrockiana Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- -1 honey or Agave syrup Chemical class 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 235000015141 kefir Nutrition 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 240000004246 Agave americana Species 0.000 description 1
- 241000107405 Cutibacterium acnes KPA171202 Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 241000751182 Staphylococcus epidermidis ATCC 12228 Species 0.000 description 1
- 241001080024 Telles Species 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003214 anti-biofilm Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Definitions
- the present invention is in the field of treatment of the skin, mucous membranes and / or hair of individuals, in particular the improvement of the cosmetic properties of the skin, mucous membranes and / or hair of individuals, and in particular of the fight against skin aging.
- the present invention relates to a fermented extract of an aerial part of violet, in particular of leaves, which is particularly suitable for use as a cosmetic active principle, in particular for combating skin aging.
- the invention also relates to a process for obtaining such a fermented extract, as well as a composition containing such an extract from fermented violet leaves, and a process for cosmetic treatment of the skin using such a composition.
- the invention further relates to such a fermented extract for its use for the treatment of acne and / or scars.
- the violet common name used to designate the plant genus Viola, is a plant in the Violaceae family .
- fermentation technology consists in using microorganisms, more particularly bacteria and / or yeasts, which break down organic matter to form fermentation products of different structures and properties depending on the type of microorganisms used. These fermentation products can find application in many fields.
- the present inventors are interested in the properties of fermented extracts of aerial parts, in particular leaves, violets, in particular of the species Viola alba (Besser, 1809), and in particular of the subspecies Viola alba subsp. dehnhardtii (Ten.) (W. Becker, 1902), commonly known as "Toulouse violet”.
- an extract of aerial part, in particular of leaves, of violet having been subjected to fermentation by a particular ferment exhibits properties which prove to be quite advantageous in the cosmetic field, and in particular in the field of the fight against skin aging, complex process resulting in the appearance of wrinkles, sagging skin and subcutaneous tissues, loss of elasticity of the skin , etc.
- the present invention thus aims to provide a violet extract which can be used as a cosmetic active principle, in particular for topical use, and which is effective for the care, protection and / or treatment of the skin.
- the invention aims in particular to ensure that this cosmetic active principle makes it possible to meet a major objective of the cosmetic field, namely to offer consumers a cosmetic composition making it possible to effectively prevent and / or slow down skin aging.
- a fermented extract of an aerial part of violet usable in particular as a cosmetic active principle.
- violet a plant of the genus Viola.
- the mixture of microorganisms used according to the invention containing at least one species of acetic bacteria and at least one species of yeast, will be designated in the present description, for convenience, by the term "ferment”.
- Acetic bacteria are defined here in a conventional manner in themselves, as bacteria whose aerobic metabolism produces acetic fermentation by redox. This metabolism is manifested specifically by a complete or partial conversion cycle of carbohydrates, primary alcohols, polyols or aldehydes, which results in particular from acetic acid.
- the aerial part of the violet used for the preparation of the fermented extract according to the invention may consist of leaves, flowers, stems, or any mixture of these.
- the method is implemented from an aerial part of violet containing violet leaves, and preferably essentially consisting of violet leaves. It is understood, by essentially consisting of violet leaves, that the aerial part selected according to the invention contains only violet leaves, to the exclusion of any other part of the plant, except in minimal quantities, that is to say say less than 1% by weight.
- the present inventors have notably discovered that the fermentation of aqueous extracts of aerial part of violet, and very particularly of violet leaves, by such a ferment, proves to be much more effective than when it is carried out with kefir grains, such as proposed by the prior art. This performance is measured in particular in terms of speed and yield of fermentation per unit of ferment used.
- the fermented extract obtained according to the invention has particularly advantageous properties for application in the cosmetic field, in particular for preventing or slowing down the effects of aging of the skin.
- the fermented violet extract according to the invention when brought into contact with skin cells, the fermented violet extract according to the invention induces an increase in the production, by these cells, of one of the proteins known to present a skin anti-aging effect, collagen.
- the fermented violet extract according to the invention can also meet one or more of the characteristics described below, used in isolation or in each of their technically operative combinations.
- the process for obtaining the fermented extract according to the invention is preferably carried out from violet of the species Viola alba, and preferably from the subspecies Viola alba subsp. dehnhardtii. As explained above, this subspecies is commonly referred to as "Toulouse violet".
- the step of aqueous extraction of an aerial part of violet can be carried out from any fresh part, for example from fresh leaves. It is preferably made from a dried part, in particular from dried leaves. It can also be carried out on the whole part or cut into pieces, as well as on a powder obtained by grinding.
- the process for obtaining the fermented extract according to the invention may comprise an initial step of powdering the aerial part, in particular of the leaves, of violet.
- the aqueous extraction step of the process for obtaining the fermented extract according to the invention can be carried out cold. It is preferably carried out hot.
- the aqueous extraction is carried out at a temperature between 50 and 95 ° C, preferably between 80 and 95 ° C, for example at a temperature of 85 ° C ⁇ 2 ° C or 90 ° C ⁇ 2 ° C.
- the aqueous extraction can be carried out by any conventional method in itself known to those skilled in the art, in particular by infusion, decoction, percolation or else maceration. It is preferably made by decoction.
- the duration of the aqueous extraction is also preferably between 20 and 60 minutes, in particular between 20 and 30 minutes.
- the quantity of solid material (aerial part of violet) used is between 10 and 30 g per liter of water.
- the aqueous extraction is carried out at 85 ° C ⁇ 2 ° C for 20 to 30 minutes, from 10 to 30 g of powder per liter of water, and preferably by decoction .
- the reaction medium is preferably subjected to filtration, so as to separate the materials insoluble in water from the liquid extract obtained.
- the process for obtaining a liquid fermented extract according to the invention then comprises a step of preparing a fermentation solution.
- This preparation comprises the mixture, with the liquid extract obtained by aqueous extraction, of one or more fermentable sugars, that is to say sugar (s) which can be fermented by microorganisms, to form in particular the alcohol.
- fermentable sugar which can be used according to the invention, mention may be made of glucose or sucrose.
- Sucrose a disaccharide formed by the condensation of two oses, a glucose molecule and a fructose molecule, is particularly preferred in the context of the invention.
- Complex products containing one or more fermentable sugars, such as honey or Agave syrup, can also be used in the context of the invention.
- the amount of fermentable sugar mixed with the liquid extract to form the fermentation solution is for example between 50 and 70 g / l.
- the bacteria are preferably used in an amount of between 10 2 and 10 8 CFU (Colony-forming Units) / ml of fermentation solution, preferably between 10 4 and 10 7 CFU / ml.
- the yeasts are preferably used in an amount between 10 2 and 10 7 CFU / ml of fermentation solution, preferably between 10 3 and 10 6 CFU / ml.
- microorganisms can be incorporated into the aqueous extract individually, or else in the form of a symbiotic ferment, that is to say a mixture of microorganisms which have naturally developed jointly in symbiosis, in particular during a culture of microorganisms. in the presence of an aqueous extract of the aerial part of violet and a fermentable sugar, for example for at least 15 days at a temperature of about 25 ° C.
- the mixture of microorganisms is supported on a solid support, preferably insoluble in water, in particular on a natural solid support produced by microorganisms, and more particularly by one or more of the microorganisms used in the composition of the ferment used according to the invention.
- the mixture of microorganisms is supported on a solid gelatinous support insoluble in water based on cellulose, hemicellulose or one of their derivatives, in particular based on hemicellulose bacterial, in particular produced by bacteria of the species Gluconobacter oxydans.
- the hemicellulose forming the solid support can correspond to the general formula:
- cellulosane is used to denote this hemicellulose.
- the incubation of the fermentation solution seeded with the mixture of microorganisms according to the invention is preferably carried out at a temperature between 25 and 30 ° C.
- the liquid fermented extract obtained is recovered.
- This recovery can in particular be carried out by filtration, so as to eliminate the solid residues contained in the liquid medium. Filtration can in particular be carried out on a filter with pore diameters of 1 ⁇ m.
- glycerin can be added to the filtrate thus obtained.
- the process for obtaining a liquid fermented extract according to the invention comprises a final stage of sterilization of the liquid fermented extract recovered at the end of the incubation, especially in moderate conditions, for example by tyndallization.
- the liquid fermented extract can be subjected to thermalization by batch heating at 70 ° C. for around thirty minutes, a few hours apart, and this three times.
- thermalization advantageously makes it possible to eliminate all the spores which may be contained in the liquid fermented extract.
- the liquid fermented extract of an aerial part of violet according to the invention preferably has a pH less than or equal to 3. It also preferably has a Brix degree less than or equal to 2, in particular between 1 and 2. It it is preferably a fermented extract of violet leaves.
- the process for obtaining a fermented extract of an aerial part of violet according to the invention can optionally comprise a final stage of lyophilization of the extract, to form a fermented extract in powder.
- This process can meet one or more of the characteristics described above with reference to the fermented extract of an aerial part of violet according to the present invention.
- compositions in particular a cosmetic composition, in particular applicable topically to the skin, mucous membranes and / or hair of an individual.
- This composition contains a fermented extract of an aerial part, in particular of leaves, of violet according to the invention, meeting one or more of the characteristics described above, in a physiologically compatible vehicle.
- physiologically compatible vehicle is intended to mean a vehicle suitable for use in contact with human and animal cells, in particular skin cells, in particular by topical application.
- this vehicle has a pleasant odor, color and feel, and it does not generate unacceptable discomfort capable of diverting a user from the composition according to the invention.
- the content of the fermented extract of an aerial part of violet according to the invention in the composition may in particular be between 0.1 and 10% by weight, relative to the total weight of the composition.
- composition according to the invention may contain one or more additional active ingredient (s), in particular ingredients with beneficial properties for the skin, the effect of which can, if necessary, be exerted in synergy with that of the fermented violet extract according to the invention.
- additional active ingredient s
- moisturizing agents emollient agents, anti-wrinkle agents, anti-radical agents, anti-UV agents, etc.
- composition according to the invention can also comprise one or more conventional additives in themselves, in particular in the cosmetic field, for example one or more perfumes, stabilizing agent (s), preserving agent (s) ( s), emulsifier (s), etc.
- perfumes for example one or more perfumes, stabilizing agent (s), preserving agent (s) ( s), emulsifier (s), etc.
- compositions for topical use in particular for skin use, in the cosmetic field, in particular in the form of a cream, an ointment, a milk, d '' a lotion, gel, serum, ointment, etc.
- Another aspect of the invention relates to a method of non-therapeutic cosmetic treatment of the skin, mucous membranes and / or hair of an individual, in particular human, this method comprising administration to this individual, in particular by application by topically on the skin, mucous membranes and / or hair of this individual, of a composition according to the invention, meeting one or more of the characteristics described above.
- the cosmetic treatment method according to the invention comprises in particular the application of the composition according to the invention topically to a healthy area, not affected by a disease, in particular by an inflammatory disease, of the skin, the mucous membranes and / or the individual's hair.
- the cosmetic treatment method according to the invention can in particular comprise the topical application, on the cutaneous surface of the concerned parts of the body of the individual in need thereof, for example on the skin of the face and the neck, of a determined amount of the composition according to the invention.
- This application can for example be carried out once or twice a day, for example in the morning and in the evening, and for example for a period between 2 weeks and 2 months or more.
- the composition according to the invention makes it possible, in particular, to prevent, or at least slow down, the appearance of skin signs of aging.
- the cosmetic treatment process according to the invention may otherwise comprise the oral administration, to the individual concerned, of the composition according to the invention.
- Another aspect of the invention relates to the use of a fermented extract of an aerial part, in particular of leaves, of violet according to the invention, meeting one or more of the above characteristics, for the non-therapeutic cosmetic treatment of the skin, mucous membranes and / or hair of an individual, in particular for combating skin aging.
- the invention relates to the use of an extract of an aerial part, in particular of leaves, of violet, in particular of the species Viola alba, and preferably of the subspecies Viola alba subsp. dehnhardtii, for the non-therapeutic cosmetic treatment of the skin, mucous membranes and / or hair of an individual, in particular to combat skin aging
- This use may in particular include the application of the violet extract topically, in particular on an area of the skin of the individual in need thereof, this area being healthy and not affected by a disease, in particular by a disease. inflammatory.
- the present invention relates to a fermented extract of an aerial part of violet according to the invention for its use for the therapeutic treatment of skin disorders, in particular with an inflammatory component, in particular for the treatment of acne and / or scars, in particular by topical application to the affected skin area of an individual, in particular human.
- This application advantageously takes advantage of the anti-inflammatory effect of the fermented extract according to the invention.
- the fermented extract of an aerial part of violet according to the invention has the capacity to slow down the appearance on the skin of biofilms of the bacteria Propionibacterium acnes and Staphylococcus epidermitis, which are involved in skin conditions such as acne ( Burkart and Burkart, 2003, Int. J. Dermatol. 42: 925-927 ), and to block the maturation of such biofilms.
- the fermented extract according to the invention does not furthermore induce intolerance, allergy or aggressive side effects in contact with the skin.
- Leaves of the species Viola alba subsp. dehnhardtii are dried, then subjected to aqueous extraction by decoction.
- the dried leaves are incorporated into 400 l of demineralized water at room temperature, at a rate of 20 g of leaves per liter of water.
- the aqueous medium is heated to 85 ° C ⁇ 2 ° C, and maintained at this temperature for 60 min, until an optical density greater than 20 to 280 nm is obtained.
- the aqueous medium is then filtered to remove solid residues.
- a fermentation solution is prepared from the filtrate thus obtained.
- sucrose is added to the filtrate at a concentration of 70 g / l.
- the medium is stirred until the sucrose is completely dissolved, then filtered to remove the remaining solid impurities.
- the fermentation solution thus obtained is seeded with a mixture of microorganisms containing bacteria of the species Acetobacter sp and Gluconobacter oxydans, and yeasts of the species Saccharomyces cerevisiae, Zygosaccharomyces sp and Schizosaccharomyces pombe, this mixture being essentially free of lactic acid bacteria and lactose fermenting yeasts.
- microorganisms are preferably trapped in a solid support insoluble in water, preferably based on hemicellulose.
- Each microorganism is used at a rate of approximately 10 6 CFU / ml of fermentation solution.
- a symbiotic ferment which has been obtained by seeding a fermentation solution containing an aqueous extract of leaves of the species Viola alba subsp. dehnhardtii and sucrose, such as the fermentation solution described above, with a mixture containing a large number of different microorganisms, and incubation at approximately 25 ° C for 15 days.
- the medium thus obtained is then incubated under static conditions at 28 ° C ( ⁇ 2 ° C) for 30 days.
- a Brix degree less than 2 and a pH less than or equal to 3 is then obtained for the reaction medium.
- This medium is subjected to filtration so as to separate the ferment on solid support from the liquid fermented extract, first on a first filter with a pore diameter of 1 ⁇ m, then on a second filter with a pore diameter of 0, 2 ⁇ m.
- the liquid fermented extract thus isolated is subjected to a treatment by tyndallization, by repeating the following cycle 3 times: heating at 70 ° C. for 20 min, cooling at room temperature for 24 h.
- the extract of fermented violet leaves then obtained is stored protected from light.
- This extract of fermented violet leaves obtained in accordance with the present invention, is analyzed by high performance liquid chromatography (HPLC). By way of comparison, the fermentation solution formed during the above production process is also analyzed, not seeded with the ferment.
- HPLC high performance liquid chromatography
- the HPLC analysis is carried out on an Agilent Poroshell 120 SB-C18 column, with injection of 10 ⁇ l of each sample (having been previously concentrated 3 times by vacuum evaporation), at a temperature of 30 ° C. and a flow rate of 0 , 8 ml / min, with detection at 210 nm.
- Eluent A water and 7.5 mM formic acid
- eluent B acetonitrile
- Eluent A water and 7.5 mM formic acid
- eluent B acetonitrile
- the results obtained are shown on the figure 1 .
- the front line shows the results obtained for the liquid solution before fermentation
- the rear line shows the results obtained for the liquid solution after fermentation.
- the leaf extract of Viola alba subsp. fermented dehnhardtii obtained in Example A / is tested for its capacity to activate the synthesis of collagen by human fibroblasts.
- primary human fibroblast cells are cultured in a suitable culture medium (DMEM medium 4.5 g / l glucose, 2 mM L-glutamine, 10% heat-inactivated fetal calf serum (SVF) , 50 IU / ml of penicillin, 50 ⁇ g / l of streptomycin), in the presence of different concentrations of the fermented extract according to the invention (5000 ⁇ g / ml, 1000 ⁇ g / ml, 500 ⁇ g / ml).
- the culture is carried out at 37 ° C. under a 5% CO 2 atmosphere.
- the growth factor TGF- ⁇ is tested at 10 ng / ml in the culture medium at 1% FCS.
- the amount of collagen present in the cell matrix and in the culture medium is determined after 48 h of culture, using Sirius red dye (Direct Red 80), which has a particular affinity for the triple structure. helix (Gly-XY) n of native collagen. The total amount of protein present is also measured by the Bradford test.
- the culture medium is removed and the cell layer is rinsed with 500 ⁇ l of protease inhibitor cocktail.
- the cell layer is then recovered by scraping in 500 ⁇ l of protease inhibitor cocktail, then the culture wells are rinsed with 500 ⁇ l of the protease inhibitor cocktail.
- the two volumes, which constitute the extracellular matrix, are combined and treated by ultrasound for 40 s.
- Collagen is complexed with the red dye Sirius. After centrifugation and washing with 0.1 M hydrochloric acid, the pellet is dissolved in a 0.5 M sodium hydroxide solution. The absorbance of the dye-collagen complex is measured at 540 nm. A calibration range is established between 0 and 50 ⁇ g per collagen tube.
- the total quantity of proteins present is also measured by the Bradford test, according to the protocol described in the publication of Bradford et al., 1976, Anal. Biochem. 72: 248-54 , against a calibration range established from a solution of BSA (bovine serum albumin) at 400 ⁇ g / ml in PBS (phosphate buffered saline).
- BSA bovine serum albumin
- the weight ratio of collagen / proteins measured by the Bradford test is calculated, as well as the% increase in the production of collagen by the cells, compared to the negative control.
- the figure 2 represents a graph showing the percentage increase in collagen production by human fibroblast cells, induced by the fermented extract according to the invention at different concentrations in the cell culture medium, and by the growth factor TGF- ⁇ , relative to the culture medium not added.
- the leaf extract of Viola alba subsp. fermented dehnhardtii obtained in Example A / is tested for its capacity to fight against biofilms of Propionibacterium acnes and against biofilms of Staphylococcus epidermitis.
- the aim of this study is to determine whether the ability of these bacteria to establish a biofilm, involved in acne, can be slowed down, and the maturation of this biofilm blocked, by the fermented extract according to the invention.
- the Biofilm Ring Test® method from Biofilm Control® is used. This method makes it possible to determine an index, called BFI (for the English BioFilm Index), which is inversely proportional to the level of production of biofilm ( Dagnelie et al., 2018, Annales de Dermatologie et de Vénéréologie 145 (12): S123 ).
- the percentage of presence of the biofilm is determined initially (at 0 h) and after respectively 2 h, 4 h, 6 h and 24 h of incubation of the bacteria with the extract according to the invention.
- the organisms used in this study are Propionibacterium acnes KPA 171202 and Staphylococcus epidermidis ATCC 12228.
- Propionibacterium acnes a liquid aliquot of bacteria is prepared according to the slightly modified method of Hayes and Markovic ( Hayes and Markovic, 2002, Food Chem Toxicol. 40: 535-543 ).
- Propionibacterium acnes cells are incubated in a medium for heart and brain perfusion (BHI) with 1% glucose for 48 h at 37 ° C and under anaerobic conditions. The medium is diluted to obtain approximately 1.0 ⁇ 10 8 CFU / ml.
- BHI heart and brain perfusion
- Staphylococcus epidermidis cells are incubated in trypticase soy broth (TSB) for 24 h at 37 ° C. under aerobic conditions, then the medium is adjusted to obtain approximately 1.0 ⁇ 10 8 CFU / ml.
- TLB trypticase soy broth
- compositions are prepared: 10 ml test tubes containing 3 ml of nutritive yeast glucose broth (NYG) for Propionibacterium acnes, or 3 ml of nutrient broth for Staphylococcus epidermidis, were autoclaved for 12 h at 150 ° C. The medium in each test tube was cooled and then inoculated with 50 ⁇ l of the bacterial suspension of Propionibacterium acnes or of Staphylococcus epidermidis containing 1x10 8 cells / ml.
- NSG nutritive yeast glucose broth
- Staphylococcus epidermidis 3 ml of nutrient broth for Staphylococcus epidermidis
- compositions based on extract according to the invention the extract according to the invention is added, respectively at 2% v / v (composition S2%) and at 4% v / v (composition S4%), in some of the test tubes above.
- Biofilm Ring Test® The principle of the Biofilm Ring Test® method is described by Chavant et al. 1997, J Med Microbiol 60: 300-306 . It is based on the addition to the bacterial solution, containing if necessary the extract to be tested, of magnetic beads of 5 or 6 ⁇ m in diameter. The mixture of magnetic beads and bacterial solution is seeded in wells, then incubated for different durations between 0h and 24h. The aerobic or anaerobic conditions necessary for the development of bacterial biofilms for each of the strains tested are respected. After the incubation period in the wells, a contrast medium is added to allow reading in the special Biofilm Reader®.
- the data collected by the reader is sent to the computer, interpreted and stored by the special Biofilm Control Elements® software.
- the wells are then inserted into the magnetizer and magnetized for 1 min.
- the beads which have not been retained in the biofilm possibly formed are attracted towards the center of the well, forming a red circle there.
- the particles are immobilized there throughout the volume of the well and the red circle disappears.
- a second reading is carried out to allow the detection of the magnetic beads deposited on the base of the well.
- the data collected after this second reading is also transmitted, interpreted and stored on the computer. From the comparison of the images obtained after the first and second readings for each well, a value called the Biofilm Formation Index (BFI) is calculated, as well as the percentage of presence of biofilm in the well.
- BFI Biofilm Formation Index
- the figure 3 shows photographs of the wells after different incubation times for the control ("T") and for the two concentrations of fermented extract according to the invention ("S2%” and "S4%") for the different incubation times , in a / for Propionibacterium acnes and in b / for Staphylococcus epidermitis.
- the witness shows that Propionibacterium acnes is 100% biofilmogenic, that is to say that the quorum sensing is maximum and produces biofilm.
- the sample according to the invention S2% shows a reduction in biofilm formation by 55%, therefore by more than half compared to the control.
- the sample according to the invention S4% shows a reduction in the formation of biofilm by 85%, that is to say that the quorum sensing could not develop the maturation of the biofilm.
- Staphylococcus epidermitis is 100% biofilmogenic, that is to say that the quorum sensing is maximum and produces biofilm.
- the sample according to the invention S2% shows a reduction in the formation of biofilm by 46% compared to the control.
- the sample according to the invention S4% shows a reduction in biofilm formation of 72%, that is to say that the quorum sensing could not develop the maturation of the biofilm.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Cosmetics (AREA)
Abstract
L'invention concerne un extrait fermenté d'une partie aérienne de violette obtenu par un procédé comprenant la préparation d'un extrait liquide par extraction aqueuse de ladite partie aérienne ; la préparation d'une solution de fermentation par mélange de cet extrait liquide avec un sucre fermentescible ; l'ensemencement de cette solution avec un mélange de microorganismes contenant au moins une espèce de bactéries acétiques et au moins une espèce de levure, ce mélange étant essentiellement dépourvu de bactéries lactiques et de levures fermentant le lactose ; l'incubation à une température inférieure ou égale à 30 °C pendant au moins 10 jours ; et la récupération de l'extrait fermenté liquide obtenu. Cet extrait fermenté trouve application en tant que principe actif cosmétique pour le soin de la peau.The invention relates to a fermented extract of an aerial part of violet obtained by a process comprising the preparation of a liquid extract by aqueous extraction of said aerial part; preparing a fermentation solution by mixing this liquid extract with a fermentable sugar; seeding this solution with a mixture of microorganisms containing at least one species of acetic bacteria and at least one species of yeast, this mixture being essentially free of lactic acid bacteria and lactose fermenting yeasts; incubation at a temperature less than or equal to 30 ° C for at least 10 days; and recovering the obtained liquid fermented extract. This fermented extract finds application as a cosmetic active principle for the care of the skin.
Description
La présente invention s'inscrit dans le domaine du traitement de la peau, des muqueuses et/ou des cheveux des individus, notamment de l'amélioration des propriétés cosmétiques de la peau, des muqueuses et/ou des cheveux des individus, et en particulier de la lutte contre le vieillissement cutané.The present invention is in the field of treatment of the skin, mucous membranes and / or hair of individuals, in particular the improvement of the cosmetic properties of the skin, mucous membranes and / or hair of individuals, and in particular of the fight against skin aging.
Plus particulièrement, la présente invention concerne un extrait fermenté d'une partie aérienne de violette, notamment de feuilles, qui est particulièrement adapté pour une utilisation en tant que principe actif cosmétique, notamment pour lutter contre le vieillissement cutané. L'invention concerne également un procédé d'obtention d'un tel extrait fermenté, ainsi qu'une composition contenant un tel extrait de feuilles de violette fermenté, et un procédé de traitement cosmétique de la peau mettant en oeuvre une telle composition. L'invention concerne en outre un tel extrait fermenté pour son utilisation pour le traitement de l'acné et/ou des cicatrices.More particularly, the present invention relates to a fermented extract of an aerial part of violet, in particular of leaves, which is particularly suitable for use as a cosmetic active principle, in particular for combating skin aging. The invention also relates to a process for obtaining such a fermented extract, as well as a composition containing such an extract from fermented violet leaves, and a process for cosmetic treatment of the skin using such a composition. The invention further relates to such a fermented extract for its use for the treatment of acne and / or scars.
La violette, nom commun utilisé pour désigner le genre végétal Viola, est une plante de la famille des Violaceae. The violet, common name used to designate the plant genus Viola, is a plant in the Violaceae family .
Diverses espèces du genre Viola sont utilisées en médecine depuis des décennies pour lutter contre divers troubles de la santé. Il a ainsi notamment été identifié et mis à profit, dans le domaine médical, des effets antifongique, antibactérien, analgésique, anti-inflammatoire et diurétique de ces espèces.Various species of the genus Viola have been used medicinally for decades to combat various health conditions. In particular, it has been identified and used in the medical field for the antifungal, antibacterial, analgesic, anti-inflammatory and diuretic effects of these species.
Le document
De manière générale, la technologie de fermentation consiste à mettre en oeuvre des microorganismes, plus particulièrement des bactéries et/ou des levures, qui décomposent la matière organique pour former des produits de fermentation de structures et de propriétés différentes en fonction du type de microorganismes utilisés. Ces produits de fermentation peuvent trouver application dans de nombreux domaines.In general, fermentation technology consists in using microorganisms, more particularly bacteria and / or yeasts, which break down organic matter to form fermentation products of different structures and properties depending on the type of microorganisms used. These fermentation products can find application in many fields.
Les présents inventeurs se sont intéressés aux propriétés des extraits fermentés de parties aériennes, notamment des feuilles, de violette, notamment de l'espèce Viola alba (Besser, 1809), et en particulier de la sous-espèce Viola alba subsp. dehnhardtii (Ten.) (W. Becker, 1902), communément nommée « violette de Toulouse ».The present inventors are interested in the properties of fermented extracts of aerial parts, in particular leaves, violets, in particular of the species Viola alba (Besser, 1809), and in particular of the subspecies Viola alba subsp. dehnhardtii (Ten.) (W. Becker, 1902), commonly known as "Toulouse violet".
Ils ont découvert au cours de leurs travaux que, de manière tout à fait surprenante, un extrait de partie aérienne, en particulier de feuilles, de violette ayant été soumis à fermentation par un ferment particulier, présente des propriétés qui s'avèrent tout à fait avantageuses dans le domaine cosmétique, et en particulier dans le domaine de la lutte contre le vieillissement cutané, processus complexe se traduisant par l'apparition de rides, le relâchement des tissus cutanés et sous-cutanés, une perte de l'élasticité de la peau, etc.They discovered during their work that, quite surprisingly, an extract of aerial part, in particular of leaves, of violet having been subjected to fermentation by a particular ferment, exhibits properties which prove to be quite advantageous in the cosmetic field, and in particular in the field of the fight against skin aging, complex process resulting in the appearance of wrinkles, sagging skin and subcutaneous tissues, loss of elasticity of the skin , etc.
La présente invention vise ainsi à proposer un extrait de violette qui soit utilisable en tant que principe actif cosmétique, notamment pour un usage par voie topique, et qui soit efficace pour le soin, la protection et/ou le traitement de la peau.The present invention thus aims to provide a violet extract which can be used as a cosmetic active principle, in particular for topical use, and which is effective for the care, protection and / or treatment of the skin.
L'invention vise notamment à ce que ce principe actif cosmétique permette de répondre à un objectif majeur du domaine cosmétique, à savoir de proposer aux consommateurs une composition cosmétique permettant de prévenir et/ou ralentir efficacement le vieillissement cutané.The invention aims in particular to ensure that this cosmetic active principle makes it possible to meet a major objective of the cosmetic field, namely to offer consumers a cosmetic composition making it possible to effectively prevent and / or slow down skin aging.
Ainsi, il est proposé selon la présente invention un extrait fermenté d'une partie aérienne de violette, utilisable notamment en tant que principe actif cosmétique. On entend dans la présente description, de manière classique en elle-même, par le terme violette, une plante du genre Viola. Thus, there is proposed according to the present invention a fermented extract of an aerial part of violet, usable in particular as a cosmetic active principle. In the present description is meant, conventionally in itself, by the term violet, a plant of the genus Viola.
Cet extrait fermenté d'une partie aérienne de violette est obtenu par un procédé d'obtention comprenant des étapes de :
- préparation d'un extrait liquide par extraction aqueuse de la partie aérienne de violette,
- préparation d'une solution dite de fermentation, par mélange de cet extrait liquide avec un sucre fermentescible,
- ensemencement de cette solution de fermentation avec un mélange de microorganismes contenant au moins une espèce de bactéries acétiques et au moins une espèce de levure, ce mélange étant essentiellement dépourvu de bactéries lactiques et de levures fermentant le lactose,
- incubation de la solution de fermentation ainsi ensemencée à une température inférieure ou égale à 30 °C, notamment comprise entre 25 et 30 °C, pendant au moins 10 jours, de préférence pendant au moins 20 jours,
- et récupération de l'extrait fermenté liquide ainsi obtenu.
- preparation of a liquid extract by aqueous extraction of the aerial part of violet,
- preparation of a so-called fermentation solution, by mixing this liquid extract with a fermentable sugar,
- inoculation of this fermentation solution with a mixture of microorganisms containing at least one species of acetic bacteria and at least one species of yeast, this mixture being essentially devoid of lactic acid bacteria and lactose-fermenting yeasts,
- incubation of the fermentation solution thus seeded at a temperature less than or equal to 30 ° C, in particular between 25 and 30 ° C, for at least 10 days, preferably for at least 20 days,
- and recovering the liquid fermented extract thus obtained.
Le mélange de microorganismes mis en oeuvre selon l'invention, contenant au moins une espèce de bactéries acétiques et au moins une espèce de levure, sera désigné dans la présente description, pour plus de commodité, par le terme « ferment ».The mixture of microorganisms used according to the invention, containing at least one species of acetic bacteria and at least one species of yeast, will be designated in the present description, for convenience, by the term "ferment".
Les bactéries acétiques sont définies ici de manière classique en elle-même, comme des bactéries dont le métabolisme aérobie produit une fermentation acétique par oxydoréduction. Ce métabolisme se manifeste spécifiquement par un cycle de conversion complet ou partiel de glucides, d'alcools primaires, de polyols ou d'aldéhydes, dont résulte en particulier de l'acide acétique.Acetic bacteria are defined here in a conventional manner in themselves, as bacteria whose aerobic metabolism produces acetic fermentation by redox. This metabolism is manifested specifically by a complete or partial conversion cycle of carbohydrates, primary alcohols, polyols or aldehydes, which results in particular from acetic acid.
Selon la présente invention, le ferment mis en oeuvre est essentiellement dépourvu, c'est-à-dire qu'il n'en contient pas, ou seulement en infimes quantités, de :
- bactéries lactiques, c'est-à-dire de bactéries aptes à produire de l'acide lactique, notamment par fermentation des sucres, en particulier des bactéries de la famille des Lactobacillaceae, et notamment du genre Lactobacillus ;
- et de levures fermentant le lactose, telles que des levures de l'espèce Kluyveromyces marxianus.
- lactic acid bacteria, that is to say bacteria capable of producing lactic acid, in particular by fermentation of sugars, in particular bacteria of the Lactobacillaceae family , and in particular of the genus Lactobacillus ;
- and lactose fermenting yeasts, such as yeasts of the species Kluyveromyces marxianus.
La partie aérienne de violette utilisée pour la préparation de l'extrait fermenté selon l'invention peut consister en des feuilles, des fleurs, des tiges, ou tout mélange de celles-ci.The aerial part of the violet used for the preparation of the fermented extract according to the invention may consist of leaves, flowers, stems, or any mixture of these.
Dans des modes de réalisation particulièrement préférés de l'invention, le procédé est mis en oeuvre à partir d'une partie aérienne de violette contenant des feuilles de violette, et préférentiellement essentiellement constituée de feuilles de violette. On entend, par essentiellement constituée de feuilles de violette, que la partie aérienne sélectionnée selon l'invention contient uniquement des feuilles de violette, à l'exclusion de toute autre partie de la plante, sauf en quantités minimes, c'est-à-dire inférieure à 1 % en poids.In particularly preferred embodiments of the invention, the method is implemented from an aerial part of violet containing violet leaves, and preferably essentially consisting of violet leaves. It is understood, by essentially consisting of violet leaves, that the aerial part selected according to the invention contains only violet leaves, to the exclusion of any other part of the plant, except in minimal quantities, that is to say say less than 1% by weight.
Les présents inventeurs ont notamment découvert que la fermentation des extraits aqueux de partie aérienne de violette, et tout particulièrement de feuilles de violette, par un tel ferment, s'avère bien plus efficace que lorsqu'elle est réalisée par des grains de kéfir, comme proposé par l'art antérieur. Cette performance se mesure notamment en termes de vitesse et de rendement de la fermentation par unité de ferment mis en oeuvre.The present inventors have notably discovered that the fermentation of aqueous extracts of aerial part of violet, and very particularly of violet leaves, by such a ferment, proves to be much more effective than when it is carried out with kefir grains, such as proposed by the prior art. This performance is measured in particular in terms of speed and yield of fermentation per unit of ferment used.
L'extrait fermenté obtenu selon l'invention présente des propriétés particulièrement avantageuses pour une application dans le domaine cosmétique, en particulier pour prévenir ou ralentir les effets du vieillissement de la peau. Il a par exemple été découvert par les présents inventeurs que mis au contact des cellules de la peau, l'extrait de violette fermenté selon l'invention induit une augmentation de la production, par ces cellules, d'une des protéines connues pour présenter un effet antivieillissement cutané, le collagène.The fermented extract obtained according to the invention has particularly advantageous properties for application in the cosmetic field, in particular for preventing or slowing down the effects of aging of the skin. For example, it has been discovered by the present inventors that when brought into contact with skin cells, the fermented violet extract according to the invention induces an increase in the production, by these cells, of one of the proteins known to present a skin anti-aging effect, collagen.
L'extrait de violette fermenté selon l'invention peut en outre répondre à l'une ou plusieurs des caractéristiques décrites ci-après, mises en oeuvre isolément ou en chacune des leurs combinaisons techniquement opérantes.The fermented violet extract according to the invention can also meet one or more of the characteristics described below, used in isolation or in each of their technically operative combinations.
Le procédé d'obtention de l'extrait fermenté selon l'invention est de préférence mis en oeuvre à partir de violette de l'espèce Viola alba, et préférentiellement de la sous-espèce Viola alba subsp. dehnhardtii. Comme exposé ci-avant, cette sous-espèce est communément désignée par l'expression « violette de Toulouse ». Les extraits fermentés conformément à la présente invention d'une partie aérienne, et tout particulièrement de feuilles, de cette plante particulière, présentent un effet anti-âge particulièrement important.The process for obtaining the fermented extract according to the invention is preferably carried out from violet of the species Viola alba, and preferably from the subspecies Viola alba subsp. dehnhardtii. As explained above, this subspecies is commonly referred to as "Toulouse violet". The extracts fermented in accordance with the present invention from an aerial part, and very particularly from the leaves, of this particular plant, have a particularly significant anti-aging effect.
L'étape d'extraction aqueuse d'une partie aérienne de violette peut être réalisée à partir de toute partie fraîche, par exemple de feuilles fraîches. Elle est de préférence réalisée à partir d'une partie séchée, notamment de feuilles séchées. Elle peut en outre aussi bien être réalisée sur la partie entière ou coupée en morceaux, que sur une poudre obtenue par broyage.The step of aqueous extraction of an aerial part of violet can be carried out from any fresh part, for example from fresh leaves. It is preferably made from a dried part, in particular from dried leaves. It can also be carried out on the whole part or cut into pieces, as well as on a powder obtained by grinding.
Ainsi, le procédé d'obtention de l'extrait fermenté selon l'invention peut comprendre une étape initiale de réduction en poudre de la partie aérienne, notamment des feuilles, de violette.Thus, the process for obtaining the fermented extract according to the invention may comprise an initial step of powdering the aerial part, in particular of the leaves, of violet.
L'étape d'extraction aqueuse du procédé d'obtention de l'extrait fermenté selon l'invention peut être réalisée à froid. Elle est de préférence réalisée à chaud.The aqueous extraction step of the process for obtaining the fermented extract according to the invention can be carried out cold. It is preferably carried out hot.
Dans des modes de mise en oeuvre particuliers de l'invention, l'extraction aqueuse est réalisée à une température comprise entre 50 et 95 °C, de préférence entre 80 et 95 °C, par exemple à une température de 85 °C ± 2 °C ou de 90 °C ± 2 °C.In particular embodiments of the invention, the aqueous extraction is carried out at a temperature between 50 and 95 ° C, preferably between 80 and 95 ° C, for example at a temperature of 85 ° C ± 2 ° C or 90 ° C ± 2 ° C.
L'extraction aqueuse peut être réalisée par tout méthode classique en elle-même connue de l'homme du métier, notamment par infusion, décoction, percolation ou encore macération. Elle est de préférence réalisée par décoction.The aqueous extraction can be carried out by any conventional method in itself known to those skilled in the art, in particular by infusion, decoction, percolation or else maceration. It is preferably made by decoction.
La durée de l'extraction aqueuse est en outre de préférence comprise entre 20 et 60 minutes, notamment entre 20 et 30 minutes.The duration of the aqueous extraction is also preferably between 20 and 60 minutes, in particular between 20 and 30 minutes.
Préférentiellement, la quantité de matière solide (partie aérienne de violette) utilisée est comprise entre 10 et 30 g par litre d'eau.Preferably, the quantity of solid material (aerial part of violet) used is between 10 and 30 g per liter of water.
Dans des modes de mise en oeuvre particuliers du procédé d'obtention de l'extrait fermenté selon l'invention, l'extraction aqueuse est réalisée à 85 °C ± 2 °C pendant 20 à 30 minutes, à partir de 10 à 30 g de poudre par litre d'eau, et de préférence par décoction.In particular embodiments of the process for obtaining of the fermented extract according to the invention, the aqueous extraction is carried out at 85 ° C ± 2 ° C for 20 to 30 minutes, from 10 to 30 g of powder per liter of water, and preferably by decoction .
A l'issue de l'étape d'extraction aqueuse, le milieu réactionnel est de préférence soumis à filtration, de sorte à séparer les matières insolubles dans l'eau de l'extrait liquide obtenu.At the end of the aqueous extraction step, the reaction medium is preferably subjected to filtration, so as to separate the materials insoluble in water from the liquid extract obtained.
Le procédé d'obtention d'un extrait fermenté liquide selon l'invention comprend ensuite une étape de préparation d'une solution de fermentation. Cette préparation comprend le mélange, avec l'extrait liquide obtenu par extraction aqueuse, d'un ou plusieurs sucres fermentescibles, c'est-à-dire de sucre(s) pouvant être fermenté(s) par les microorganismes, pour former notamment de l'alcool.The process for obtaining a liquid fermented extract according to the invention then comprises a step of preparing a fermentation solution. This preparation comprises the mixture, with the liquid extract obtained by aqueous extraction, of one or more fermentable sugars, that is to say sugar (s) which can be fermented by microorganisms, to form in particular the alcohol.
A titre d'exemples de sucre fermentescible pouvant être mis en oeuvre selon l'invention, on peut citer le glucose ou le saccharose. Le saccharose, disaccharide constitué par la condensation de deux oses, une molécule de glucose et une molécule de fructose, est particulièrement préféré dans le cadre de l'invention. Des produits complexes contenant un ou des sucres fermentescibles, tels que le miel ou le sirop d'Agave, peuvent également être utilisé dans le cadre de l'invention.As examples of fermentable sugar which can be used according to the invention, mention may be made of glucose or sucrose. Sucrose, a disaccharide formed by the condensation of two oses, a glucose molecule and a fructose molecule, is particularly preferred in the context of the invention. Complex products containing one or more fermentable sugars, such as honey or Agave syrup, can also be used in the context of the invention.
La quantité de sucre fermentescible mélangé à l'extrait liquide pour former la solution de fermentation est par exemple comprise entre 50 et 70 g/l.The amount of fermentable sugar mixed with the liquid extract to form the fermentation solution is for example between 50 and 70 g / l.
Dans des modes de mise en oeuvre particulièrement avantageux du procédé d'obtention d'un extrait fermenté selon l'invention, le mélange de microorganismes (ferment) mis en oeuvre contient :
- au moins une, de préférence plusieurs, espèces de bactéries acétiques, en particulier au moins une, de préférence plusieurs, espèces de bactéries du genre Acetobacter, par exemple Acetobacter sp, et/ou du genre Gluconobacter, par exemple Gluconobacter oxydans ;
- et au moins une, de préférence plusieurs, espèces de levure, en particulier au moins une, de préférence plusieurs, espèces de levures de la famille des Saccharomycetaceae, notamment du genre Saccharomyces, par exemple Saccharomyces cerevisiae, ou du genre Zygosaccharomyces, par exemple Zygosaccharomyces sp, et/ou de la famille des Schizosaccharomycetaceae, notamment du genre Schizosaccharomyces, par exemple Schizosaccharomyces pombe.
- at least one, preferably several, species of acetic bacteria, in particular at least one, preferably several, species of bacteria of the genus Acetobacter, for example Acetobacter sp, and / or of the genus Gluconobacter, for example Gluconobacter oxidans ;
- and at least one, preferably several, yeast species, in particular at least one, preferably several, yeast species of the family of Saccharomycetaceae, in particular of the genus Saccharomyces, for example Saccharomyces cerevisiae, or of the genus Zygosaccharomyces, for example Zygosaccharomyces sp, and / or of the family of Schizosaccharomycetaceae, in particular of the genus Schizosaccharomyces, for example Schizosaccharomyces pombe.
Pour l'ensemencement, il peut être utilisé différentes quantités de chacun des microorganismes entrant dans la composition du ferment, à tout rapport pondéral des uns par rapport aux autres.For sowing, different quantities of each of the microorganisms entering into the composition of the ferment can be used, in any weight ratio of one to the other.
Les bactéries sont de préférence utilisées dans une quantité comprise entre 102 et 108 UFC (Unités Formant Colonies)/ml de solution de fermentation, de préférence comprise entre 104 et 107 UFC/ml.The bacteria are preferably used in an amount of between 10 2 and 10 8 CFU (Colony-forming Units) / ml of fermentation solution, preferably between 10 4 and 10 7 CFU / ml.
Les levures sont quant à elles de préférence utilisées dans une quantité comprise entre 102 et 107 UFC/ml de solution de fermentation, de préférence comprise entre 103 et 106 UFC/ml.The yeasts are preferably used in an amount between 10 2 and 10 7 CFU / ml of fermentation solution, preferably between 10 3 and 10 6 CFU / ml.
Les microorganismes peuvent être incorporés dans l'extrait aqueux isolément, ou bien sous forme de ferment symbiotique, c'est-à-dire d'un mélange de microorganismes s'étant naturellement développés conjointement en symbiose, notamment lors d'une culture de microorganismes en présence d'un extrait aqueux de la partie aérienne de violette et d'un sucre fermentescible, par exemple pendant au moins 15 jours à une température d'environ 25 °C.The microorganisms can be incorporated into the aqueous extract individually, or else in the form of a symbiotic ferment, that is to say a mixture of microorganisms which have naturally developed jointly in symbiosis, in particular during a culture of microorganisms. in the presence of an aqueous extract of the aerial part of violet and a fermentable sugar, for example for at least 15 days at a temperature of about 25 ° C.
Dans des modes de mise en oeuvre particuliers du procédé d'obtention d'un extrait fermenté selon l'invention, le mélange de microorganismes est supporté sur un support solide, de préférence insoluble dans l'eau, notamment sur un support solide naturel produit par des microorganismes, et plus particulièrement par un ou plusieurs des microorganismes entrant dans la composition du ferment mis en oeuvre selon l'invention.In particular embodiments of the process for obtaining a fermented extract according to the invention, the mixture of microorganisms is supported on a solid support, preferably insoluble in water, in particular on a natural solid support produced by microorganisms, and more particularly by one or more of the microorganisms used in the composition of the ferment used according to the invention.
Préférentiellement, le mélange de microorganismes est supporté sur un support solide gélatineux insoluble dans l'eau à base de cellulose, d'hémicellulose ou d'un de leurs dérivés, notamment à base d'hémicellulose bactérienne, en particulier produite par les bactéries de l'espèce Gluconobacter oxydans. Preferably, the mixture of microorganisms is supported on a solid gelatinous support insoluble in water based on cellulose, hemicellulose or one of their derivatives, in particular based on hemicellulose bacterial, in particular produced by bacteria of the species Gluconobacter oxydans.
A titre d'exemple, l'hémicellulose formant le support solide peut répondre à la formule générale :
Le terme cellulosane est utilisé pour désigner cette hémicellulose.The term cellulosane is used to denote this hemicellulose.
L'incubation de la solution de fermentation ensemencée par le mélange de microorganismes selon l'invention est de préférence réalisée à une température comprise entre 25 et 30 °C.The incubation of the fermentation solution seeded with the mixture of microorganisms according to the invention is preferably carried out at a temperature between 25 and 30 ° C.
Elle est en outre préférentiellement réalisée pendant une durée comprise entre 20 et 30 jours.It is also preferably carried out for a period of between 20 and 30 days.
A l'issue de cette étape d'incubation, l'extrait fermenté liquide obtenu est récupéré. Cette récupération peut notamment être réalisée par filtration, de sorte à éliminer les résidus solides contenus dans le milieu liquide. La filtration peut notamment être réalisée sur un filtre de diamètres de pores d'1 µm.At the end of this incubation step, the liquid fermented extract obtained is recovered. This recovery can in particular be carried out by filtration, so as to eliminate the solid residues contained in the liquid medium. Filtration can in particular be carried out on a filter with pore diameters of 1 μm.
Le cas échéant, de la glycérine peut être ajoutée au filtrat ainsi obtenu.If necessary, glycerin can be added to the filtrate thus obtained.
Dans des modes de mise en oeuvre particuliers de l'invention, le procédé d'obtention d'un extrait fermenté liquide selon l'invention comprend une étape finale de stérilisation de l'extrait fermenté liquide récupéré à l'issue de l'incubation, notamment en conditions modérées, par exemple par tyndallisation.In particular embodiments of the invention, the process for obtaining a liquid fermented extract according to the invention comprises a final stage of sterilization of the liquid fermented extract recovered at the end of the incubation, especially in moderate conditions, for example by tyndallization.
A titre d'exemple, l'extrait fermenté liquide peut être soumis à tyndallisation par chauffage discontinu à 70 °C pendant une trentaine de minutes, à quelques heures d'intervalle, et ce à trois reprises. Un tel traitement permet avantageusement d'éliminer toutes les spores pouvant être contenues dans l'extrait fermenté liquide.By way of example, the liquid fermented extract can be subjected to thermalization by batch heating at 70 ° C. for around thirty minutes, a few hours apart, and this three times. Such a treatment advantageously makes it possible to eliminate all the spores which may be contained in the liquid fermented extract.
L'extrait fermenté liquide d'une partie aérienne de violette selon l'invention présente de préférence un pH inférieur ou égal à 3. Il présente en outre de préférence un degré Brix inférieur ou égal à 2, notamment compris entre 1 et 2. Il s'agit préférentiellement d'un extrait fermenté de feuilles de violette.The liquid fermented extract of an aerial part of violet according to the invention preferably has a pH less than or equal to 3. It also preferably has a Brix degree less than or equal to 2, in particular between 1 and 2. It it is preferably a fermented extract of violet leaves.
Le procédé d'obtention d'un extrait fermenté d'une partie aérienne de violette selon l'invention peut optionnellement comprendre une étape finale de lyophilisation de l'extrait, pour former un extrait fermenté en poudre.The process for obtaining a fermented extract of an aerial part of violet according to the invention can optionally comprise a final stage of lyophilization of the extract, to form a fermented extract in powder.
Selon un autre aspect, la présente invention concerne un procédé d'obtention d'un extrait fermenté de partie aérienne de violette selon la présente invention. Ce procédé comprend des étapes de :
- préparation d'un extrait liquide par extraction aqueuse de la partie aérienne, notamment de feuilles, de violette,
- préparation d'une solution dite de fermentation par mélange de cet extrait liquide avec un sucre fermentescible,
- ensemencement de cette solution de fermentation avec un mélange de microorganismes contenant au moins une espèce de bactéries acétiques et au moins une espèce de levure, ce mélange étant essentiellement dépourvu de bactéries lactiques et de levures fermentant le lactose,
- incubation de la solution de fermentation ainsi ensemencée à une température inférieure ou égale à 30 °C pendant au moins 10 jours, de préférence pendant au moins 20 jours,
- et récupération de l'extrait fermenté liquide obtenu.
- preparation of a liquid extract by aqueous extraction of the aerial part, in particular from leaves, violets,
- preparation of a so-called fermentation solution by mixing this liquid extract with a fermentable sugar,
- inoculation of this fermentation solution with a mixture of microorganisms containing at least one species of acetic bacteria and at least one species of yeast, this mixture being essentially devoid of lactic acid bacteria and lactose-fermenting yeasts,
- incubation of the fermentation solution thus sown at a temperature less than or equal to 30 ° C for at least 10 days, preferably for at least 20 days,
- and recovering the liquid fermented extract obtained.
Ce procédé peut répondre à l'une ou plusieurs des caractéristiques décrites ci-avant en référence à l'extrait fermenté d'une partie aérienne de violette selon la présente invention.This process can meet one or more of the characteristics described above with reference to the fermented extract of an aerial part of violet according to the present invention.
Un autre aspect de la présente invention concerne une composition, en particulier une composition cosmétique, notamment applicable par voie topique sur la peau, les muqueuses et/ou les cheveux d'un individu. Cette composition contient un extrait fermenté d'une partie aérienne, en particulier de feuilles, de violette selon l'invention, répondant à l'une ou plusieurs des caractéristiques décrites ci-avant, dans un véhicule physiologiquement compatible.Another aspect of the present invention relates to a composition, in particular a cosmetic composition, in particular applicable topically to the skin, mucous membranes and / or hair of an individual. This composition contains a fermented extract of an aerial part, in particular of leaves, of violet according to the invention, meeting one or more of the characteristics described above, in a physiologically compatible vehicle.
On entend, par véhicule physiologiquement compatible, un véhicule adapté à une utilisation au contact de cellules humaines et animales, en particulier de cellules de la peau, notamment par application par voie topique. De préférence, ce véhicule présente une odeur, une couleur et un toucher agréables, et il ne génère pas d'inconforts inacceptables susceptibles de détourner un utilisateur de la composition selon l'invention.The term “physiologically compatible vehicle” is intended to mean a vehicle suitable for use in contact with human and animal cells, in particular skin cells, in particular by topical application. Preferably, this vehicle has a pleasant odor, color and feel, and it does not generate unacceptable discomfort capable of diverting a user from the composition according to the invention.
La teneur en l'extrait fermenté d'une partie aérienne de violette selon l'invention dans la composition peut notamment être comprise entre 0,1 et 10 % en poids, par rapport au poids total de la composition.The content of the fermented extract of an aerial part of violet according to the invention in the composition may in particular be between 0.1 and 10% by weight, relative to the total weight of the composition.
Outre l'extrait fermenté d'une partie aérienne de violette selon l'invention, tel qu'il a été décrit ci-avant, la composition selon l'invention peut contenir un ou plusieurs ingrédient(s) actif(s) supplémentaires, notamment des ingrédients à propriétés bénéfiques pour la peau, et dont l'effet peut le cas échéant s'exercer en synergie avec celui de l'extrait de violette fermenté selon l'invention. A titre d'exemples, on peut notamment citer les agents hydratants, les agents émollients, les agents antirides, les agents antiradicalaires, les agents anti-UV, etc.In addition to the fermented extract of an aerial part of violet according to the invention, as described above, the composition according to the invention may contain one or more additional active ingredient (s), in particular ingredients with beneficial properties for the skin, the effect of which can, if necessary, be exerted in synergy with that of the fermented violet extract according to the invention. By way of examples, mention may in particular be made of moisturizing agents, emollient agents, anti-wrinkle agents, anti-radical agents, anti-UV agents, etc.
La composition selon l'invention peut également comporter un ou plusieurs additifs classiques en eux-mêmes, notamment dans le domaine cosmétique, par exemple un ou des parfum(s), agent(s) stabilisateur(s), agent(s) conservateur(s), émulsifiant(s), etc.The composition according to the invention can also comprise one or more conventional additives in themselves, in particular in the cosmetic field, for example one or more perfumes, stabilizing agent (s), preserving agent (s) ( s), emulsifier (s), etc.
Cette composition peut se présenter sous toute forme classique en elle-même, notamment pour des compositions à usage topique, en particulier cutané, dans le domaine cosmétique, notamment sous forme d'une crème, d'une pommade, d'un lait, d'une lotion, d'un gel, d'un sérum, d'un onguent, etc.This composition may be in any conventional form in itself, in particular for compositions for topical use, in particular for skin use, in the cosmetic field, in particular in the form of a cream, an ointment, a milk, d '' a lotion, gel, serum, ointment, etc.
Un autre aspect de l'invention concerne un procédé de traitement cosmétique non-thérapeutique de la peau, des muqueuses et/ou des cheveux d'un individu, notamment humain, ce procédé comprenant l'administration à cet individu, notamment par application par voie topique sur la peau, les muqueuses et/ou les cheveux de cet individu, d'une composition selon l'invention, répondant à l'une ou plusieurs des caractéristiques décrites ci-avant.Another aspect of the invention relates to a method of non-therapeutic cosmetic treatment of the skin, mucous membranes and / or hair of an individual, in particular human, this method comprising administration to this individual, in particular by application by topically on the skin, mucous membranes and / or hair of this individual, of a composition according to the invention, meeting one or more of the characteristics described above.
Le procédé de traitement cosmétique selon l'invention comprend notamment l'application de la composition selon l'invention par voie topique sur une zone saine, non atteinte par une maladie, en particulier par une maladie inflammatoire, de la peau, des muqueuses et/ou des cheveux de l'individu.The cosmetic treatment method according to the invention comprises in particular the application of the composition according to the invention topically to a healthy area, not affected by a disease, in particular by an inflammatory disease, of the skin, the mucous membranes and / or the individual's hair.
Le procédé de traitement cosmétique selon l'invention peut notamment comprendre l'application par voie topique, sur la surface cutanée des parties concernées du corps de l'individu en ayant besoin, par exemple sur la peau du visage et du cou, d'une quantité déterminée de la composition selon l'invention.The cosmetic treatment method according to the invention can in particular comprise the topical application, on the cutaneous surface of the concerned parts of the body of the individual in need thereof, for example on the skin of the face and the neck, of a determined amount of the composition according to the invention.
Cette application peut par exemple être réalisée à raison d'une ou deux fois par jour, par exemple le matin et le soir, et par exemple pendant une période comprise entre 2 semaines et 2 mois ou plus.This application can for example be carried out once or twice a day, for example in the morning and in the evening, and for example for a period between 2 weeks and 2 months or more.
Appliquée par voie topique sur la peau, la composition selon l'invention permet notamment avantageusement de prévenir, ou du moins ralentir, l'apparition des signes cutanés du vieillissement.Applied topically to the skin, the composition according to the invention makes it possible, in particular, to prevent, or at least slow down, the appearance of skin signs of aging.
Le procédé de traitement cosmétique selon l'invention peut autrement comprendre l'administration par voie orale, à l'individu concerné, de la composition selon l'invention.The cosmetic treatment process according to the invention may otherwise comprise the oral administration, to the individual concerned, of the composition according to the invention.
Un autre aspect de l'invention concerne l'utilisation d'un fermenté extrait d'une partie aérienne, notamment de feuilles, de violette selon l'invention, répondant à l'une ou plusieurs des caractéristiques ci-avant, pour le traitement cosmétique non-thérapeutique de la peau, des muqueuses et/ou des cheveux d'un individu, en particulier pour lutter contre le vieillissement cutané.Another aspect of the invention relates to the use of a fermented extract of an aerial part, in particular of leaves, of violet according to the invention, meeting one or more of the above characteristics, for the non-therapeutic cosmetic treatment of the skin, mucous membranes and / or hair of an individual, in particular for combating skin aging.
Plus généralement, l'invention concerne l'utilisation d'un extrait d'une partie aérienne, notamment de feuilles, de violette, en particulier de l'espèce Viola alba, et préférentiellement de la sous-espèce Viola alba subsp. dehnhardtii, pour le traitement cosmétique non-thérapeutique de la peau, des muqueuses et/ou des cheveux d'un individu, en particulier pour lutter contre le vieillissement cutanéMore generally, the invention relates to the use of an extract of an aerial part, in particular of leaves, of violet, in particular of the species Viola alba, and preferably of the subspecies Viola alba subsp. dehnhardtii, for the non-therapeutic cosmetic treatment of the skin, mucous membranes and / or hair of an individual, in particular to combat skin aging
Cette utilisation peut notamment comprendre l'application de l'extrait de violette par voie topique, en particulier sur une zone de la peau de l'individu en ayant besoin, cette zone étant saine et non atteinte par une maladie, en particulier par une maladie inflammatoire.This use may in particular include the application of the violet extract topically, in particular on an area of the skin of the individual in need thereof, this area being healthy and not affected by a disease, in particular by a disease. inflammatory.
Selon un autre aspect, la présente invention concerne un extrait fermenté d'une partie aérienne de violette selon l'invention pour son utilisation pour le traitement thérapeutique de désordres cutanés, en particulier à composante inflammatoire, notamment pour le traitement de l'acné et/ou des cicatrices, en particulier par application par voie topique sur la zone de peau affectée d'un individu, notamment humain. Cette application tire avantageusement profit de l'effet anti-inflammatoire de l'extrait fermenté selon l'invention.According to another aspect, the present invention relates to a fermented extract of an aerial part of violet according to the invention for its use for the therapeutic treatment of skin disorders, in particular with an inflammatory component, in particular for the treatment of acne and / or scars, in particular by topical application to the affected skin area of an individual, in particular human. This application advantageously takes advantage of the anti-inflammatory effect of the fermented extract according to the invention.
En particulier, concernant le traitement de l'acné, il a été découvert par les présents inventeurs que, de manière tout à fait surprenante, l'extrait fermenté d'une partie aérienne de violette selon l'invention a la capacité de freiner l'apparition sur la peau de biofilms des bactéries Propionibacterium acnes et Staphylococcus epidermitis, qui sont impliqués dans des affections cutanées telles que l'acné (
De manière tout à fait avantageuse, l'extrait fermenté selon l'invention n'induit en outre pas d'intolérance, d'allergie ou d'effets secondaires agressifs au contact de la peau.In an entirely advantageous manner, the fermented extract according to the invention does not furthermore induce intolerance, allergy or aggressive side effects in contact with the skin.
Les caractéristiques et avantages de l'invention apparaîtront plus clairement à la lumière des exemples de mise en oeuvre ci-après, fournis à simple titre illustratif et nullement limitatifs de l'invention, avec l'appui des
- la
figure 1 représente des profils obtenus par analyse HPLC respectivement pour une solution de fermentation (non ensemencée) obtenue en produit intermédiaire lors de la mise en oeuvre d'un procédé d'obtention d'un extrait fermenté de feuilles de Viola alba subsp. dehnhardtii selon l'invention (ligne avant), et pour un extrait fermenté de feuilles de Viola alba subsp. dehnhardtii selon l'invention, obtenu après fermentation de ladite solution de fermentation (ligne arrière), montrant uniquement les pics dont l'aire brute diffère entre les deux solutions ci-avant ; - la
figure 2 représente un graphe montrant le pourcentage d'augmentation de la quantité de collagène dans la matrice cellulaire de cellules de fibroblastes humains, induite par un extrait fermenté de feuilles de Viola alba subsp. dehnhardtii selon l'invention à différentes concentrations dans le milieu de culture des cellules, et par le facteur de croissance TGF-β à titre de contrôle positif, ce pourcentage étant calculé par rapport au milieu de culture non additionné ; - la
figure 3 montre des photographies de puits obtenus à l'issue de la mise en oeuvre du test Biofilm Ring Test® pour un témoin (« T ») et pour des compositions contenant différentes concentrations d'un extrait fermenté selon l'invention (« S2% » et « S4% »), vis-à-vis de bactéries respectivement Propionibacterium acnes (a/) et Staphylococcus epidermitis (b/) après des temps d'incubation respectivement de 0h, 2h, 4h, 6h et 24h ; - la
figure 4 montre un graphe en barres représentant le pourcentage de présence de biofilm, calculé par le test Biofilm Ring Test®, pour un témoin (« T ») et pour des compositions contenant différentes concentrations d'un extrait fermenté selon l'invention (« S2% » et « S4% »), vis-à-vis de la bactérie Propionibacterium acnes après un temps d'incubation de 24h ; - et la
figure 5 montre un graphe en barres représentant le pourcentage de présence de biofilm, calculé par le test Biofilm Ring Test®, pour un témoin (« T ») et pour des compositions contenant différentes concentrations d'un extrait fermenté selon l'invention (« S2% » et « S4% »), vis-à-vis de la bactérie Staphylococcus epidermitis après un temps d'incubation de 24h.
- the
figure 1 represents profiles obtained by HPLC analysis respectively for a fermentation solution (not seeded) obtained as an intermediate product during the implementation of a process for obtaining a fermented extract of leaves of Viola alba subsp. dehnhardtii according to the invention (front line), and for a fermented extract of leaves of Viola alba subsp. dehnhardtii according to the invention, obtained after fermentation of said fermentation solution (rear line), showing only the peaks whose gross area differs between the two solutions above; - the
figure 2 represents a graph showing the percentage increase in the amount of collagen in the cellular matrix of human fibroblast cells, induced by a fermented extract of leaves of Viola alba subsp. dehnhardtii according to the invention at different concentrations in the cell culture medium, and by the growth factor TGF-β as a positive control, this percentage being calculated relative to the culture medium not added; - the
figure 3 shows photographs of wells obtained at the end of the implementation of the Biofilm Ring Test® test for a control (“T”) and for compositions containing different concentrations of a fermented extract according to the invention (“S2%” and “S4%”), with respect to bacteria respectively Propionibacterium acnes (a /) and Staphylococcus epidermitis (b /) after incubation times of 0h, 2h, 4h, 6h and 24h respectively; - the
figure 4 shows a bar graph representing the percentage presence of biofilm, calculated by the Biofilm Ring Test® test, for a control ("T") and for compositions containing different concentrations of a fermented extract according to the invention ("S2%" and "S4%"), vis-à-vis the bacteria Propionibacterium acnes after an incubation time of 24 hours; - and the
figure 5 shows a bar graph representing the percentage of presence of biofilm, calculated by the Biofilm Ring Test® test, for a control ("T") and for compositions containing different concentrations of a fermented extract according to the invention ("S2% "And" S4% "), vis-à-vis the bacteria Staphylococcus epidermitis after an incubation time of 24 hours.
Il est mis en oeuvre le procédé d'obtention conforme à l'invention suivant.The process for obtaining according to the following invention is implemented.
Des feuilles de l'espèce Viola alba subsp. dehnhardtii sont séchées, puis soumises à extraction aqueuse par décoction.Leaves of the species Viola alba subsp. dehnhardtii are dried, then subjected to aqueous extraction by decoction.
A cet effet, les feuilles séchées sont incorporées dans 400 l d'eau déminéralisée à température ambiante, à raison de 20 g de feuilles par litre d'eau. Le milieu aqueux est chauffé jusqu'à 85 °C ± 2 °C, et maintenu à cette température pendant 60 min, jusqu'à obtenir une densité optique supérieure à 20 à 280 nm.For this purpose, the dried leaves are incorporated into 400 l of demineralized water at room temperature, at a rate of 20 g of leaves per liter of water. The aqueous medium is heated to 85 ° C ± 2 ° C, and maintained at this temperature for 60 min, until an optical density greater than 20 to 280 nm is obtained.
Le milieu aqueux est ensuite filtré pour éliminer les résidus solides.The aqueous medium is then filtered to remove solid residues.
Une solution de fermentation est préparée à partir du filtrat ainsi obtenu.A fermentation solution is prepared from the filtrate thus obtained.
Pour cela, du saccharose est ajouté dans le filtrat à une concentration de 70 g/l. Le milieu est agité jusqu'à dissolution complète du saccharose, puis filtré pour éliminer les impuretés solides restantes.For this, sucrose is added to the filtrate at a concentration of 70 g / l. The medium is stirred until the sucrose is completely dissolved, then filtered to remove the remaining solid impurities.
La solution de fermentation ainsi obtenue est ensemencée par un mélange de microorganismes contenant des bactéries des espèces Acetobacter sp et Gluconobacter oxydans, et des levures des espèces Saccharomyces cerevisiae, Zygosaccharomyces sp et Schizosaccharomyces pombe, ce mélange étant essentiellement dépourvu de bactéries lactiques et de levures fermentant le lactose.The fermentation solution thus obtained is seeded with a mixture of microorganisms containing bacteria of the species Acetobacter sp and Gluconobacter oxydans, and yeasts of the species Saccharomyces cerevisiae, Zygosaccharomyces sp and Schizosaccharomyces pombe, this mixture being essentially free of lactic acid bacteria and lactose fermenting yeasts.
Les microorganismes sont de préférence entrappés dans un support solide insoluble dans l'eau, de préférence à base d'hémicellulose.The microorganisms are preferably trapped in a solid support insoluble in water, preferably based on hemicellulose.
Chaque microorganisme est mis en oeuvre à raison d'environ 106 UFC/ml de solution de fermentation.Each microorganism is used at a rate of approximately 10 6 CFU / ml of fermentation solution.
Préférentiellement, il est mis en oeuvre un ferment symbiotique qui a été obtenu par ensemencement d'une solution de fermentation contenant un extrait aqueux de feuilles de l'espèce Viola alba subsp. dehnhardtii et de saccharose, telle que la solution de fermentation décrite ci-avant, avec un mélange contenant un grand nombre de microorganismes différents, et incubation à environ 25 °C pendant 15 jours. Après 15 jours d'incubation, il s'est formé dans la solution un produit polymère, le cellulosane, qui emprisonne un mélange de microorganismes particulier, contenant des bactéries des espèces Acetobacter sp et Gluconobacter oxydans et des levures des espèces Saccharomyces cerevisiae, Zygosaccharomyces sp et Schizosaccharomyces pombe, ce mélange étant essentiellement dépourvu de bactéries lactiques et de levures fermentant le lactose. Après filtration, on récupère ce ferment symbiotique sur support solide.Preferably, a symbiotic ferment is used which has been obtained by seeding a fermentation solution containing an aqueous extract of leaves of the species Viola alba subsp. dehnhardtii and sucrose, such as the fermentation solution described above, with a mixture containing a large number of different microorganisms, and incubation at approximately 25 ° C for 15 days. After 15 days of incubation, a polymer product, cellulosane, was formed in the solution, which traps a particular mixture of microorganisms, containing bacteria of the species Acetobacter sp and Gluconobacter oxydans and yeasts of the species Saccharomyces cerevisiae, Zygosaccharomyces sp and Schizosaccharomyces pombe, this mixture being essentially devoid of lactic acid bacteria and lactose-fermenting yeasts. After filtration, this symbiotic ferment is recovered on a solid support.
20 kg de ce ferment sont incorporés dans la solution de fermentation.20 kg of this ferment are incorporated into the fermentation solution.
Le milieu ainsi obtenu est ensuite incubé en conditions statiques à 28 °C (± 2 °C) pendant 30 jours.The medium thus obtained is then incubated under static conditions at 28 ° C (± 2 ° C) for 30 days.
On obtient alors pour le milieu réactionnel un degré Brix inférieur à 2 et un pH inférieur ou égal à 3.A Brix degree less than 2 and a pH less than or equal to 3 is then obtained for the reaction medium.
Ce milieu est soumis à filtration de sorte à séparer le ferment sur support solide de l'extrait fermenté liquide, tout d'abord sur un premier filtre de diamètre de pores de 1 µm, puis sur un deuxième filtre de diamètre de pores de 0,2 µm.This medium is subjected to filtration so as to separate the ferment on solid support from the liquid fermented extract, first on a first filter with a pore diameter of 1 μm, then on a second filter with a pore diameter of 0, 2 µm.
L'extrait fermenté liquide ainsi isolé est soumis à un traitement par tyndallisation, par répétition à 3 reprises du cycle suivant : chauffage à 70 °C pendant 20 min, refroidissement à température ambiante pendant 24 h.The liquid fermented extract thus isolated is subjected to a treatment by tyndallization, by repeating the following cycle 3 times: heating at 70 ° C. for 20 min, cooling at room temperature for 24 h.
L'extrait de feuilles de violettes fermenté alors obtenu est stocké à l'abri de la lumière.The extract of fermented violet leaves then obtained is stored protected from light.
Cet extrait de feuilles de violettes fermenté, obtenu conformément à la présente invention, est analysé par chromatographie liquide haute performance (HPLC). A titre comparatif, il est également analysé la solution de fermentation formée au cours du procédé d'obtention ci-dessus, non ensemencée par le ferment.This extract of fermented violet leaves, obtained in accordance with the present invention, is analyzed by high performance liquid chromatography (HPLC). By way of comparison, the fermentation solution formed during the above production process is also analyzed, not seeded with the ferment.
L'analyse HPLC est réalisée sur une colonne Agilent Poroshell 120 SB-C18, avec injection de 10 µl de chaque échantillon (ayant au préalable été concentré 3 fois par évaporation sous vide), à une température de 30 °C et un débit de 0,8 ml/min, avec détection à 210 nm. L'éluant A (eau et acide formique 7,5 mM) et l'éluant B (acétonitrile) sont utilisés en mode gradient, comme suit :
0 min A 95 % B 5 % ; 3 min A 95% B 5%, ; 10 min A 92% B 8% ; 12 min A 90% B 10%; 17 min A 87% B13 % ; 20 min A 80% B 20% ; 27 min A 70% B 30 % ; 30 min A 50% B 50% ; 31 min A 0% B100% ; 34 min A 0% B 100% ; 35 min A 95% B 5% ; 38 min A 95% B 5%.The HPLC analysis is carried out on an Agilent Poroshell 120 SB-C18 column, with injection of 10 μl of each sample (having been previously concentrated 3 times by vacuum evaporation), at a temperature of 30 ° C. and a flow rate of 0 , 8 ml / min, with detection at 210 nm. Eluent A (water and 7.5 mM formic acid) and eluent B (acetonitrile) are used in gradient mode, as follows:
0 min A 95% B 5%; 3 min A 95% B 5%,; 10 min A 92% B 8%; 12 min A 90
Les résultats obtenus sont montrés sur la
On observe clairement une modification importante de la composition de la solution due à la fermentation.There is clearly a significant change in the composition of the solution due to fermentation.
Le procédé décrit dans l'exemple A/ ci-avant est mis en oeuvre à partir de feuilles d'autres espèces de violettes :
- Viola tricolor (communément nommée pensée sauvage),
- Viola odorata (communément nommée violette odorante).
- Viola tricolor (commonly known as wild pansy),
- Viola odorata (commonly known as fragrant violet).
Pour chacune de ces espèces, on obtient un extrait fermenté conforme à l'invention.For each of these species, a fermented extract is obtained in accordance with the invention.
L'extrait de feuilles de Viola alba subsp. dehnhardtii fermenté obtenu à l'exemple A/ est testé pour sa capacité à activer la synthèse de collagène par des fibroblastes humains.The leaf extract of Viola alba subsp. fermented dehnhardtii obtained in Example A / is tested for its capacity to activate the synthesis of collagen by human fibroblasts.
A cet effet, des cellules de fibroblaste humain primaires sont cultivées dans un milieu de culture adapté (milieu DMEM 4,5 g/l glucose, 2 mM de L-glutamine, 10 % de sérum de veau foetal (SVF) inactivé à la chaleur, 50 UI/ml de pénicilline, 50 µg/l de streptomycine), en présence de différentes concentrations de l'extrait fermenté selon l'invention (5000 µg/ml, 1000 µg/ml, 500 µg/ml). La culture est réalisée à 37 °C sous atmosphère 5 % CO2.For this purpose, primary human fibroblast cells are cultured in a suitable culture medium (DMEM medium 4.5 g / l glucose, 2 mM L-glutamine, 10% heat-inactivated fetal calf serum (SVF) , 50 IU / ml of penicillin, 50 μg / l of streptomycin), in the presence of different concentrations of the fermented extract according to the invention (5000 μg / ml, 1000 μg / ml, 500 μg / ml). The culture is carried out at 37 ° C. under a 5% CO 2 atmosphere.
A titre de contrôle négatif, il est testé l'effet du milieu de culture seul, c'est-à-dire non additionné de l'extrait fermenté selon l'invention, à 1 % de SVF. A titre de contrôle positif, il est testé le facteur de croissance TGF-β à 10 ng/ml dans le milieu de culture à 1 % de SVF.As a negative control, the effect of the culture medium alone, that is to say not added with the fermented extract according to the invention, at 1% of FCS, is tested. As a positive control, the growth factor TGF-β is tested at 10 ng / ml in the culture medium at 1% FCS.
Pour chaque échantillon testé, la quantité de collagène présente dans la matrice cellulaire et dans le milieu de culture est déterminée après 48 h de culture, au moyen de colorant rouge Sirius (Direct Red 80), qui présente une affinité particulière pour la structure triple-hélice (Gly-X-Y)n du collagène natif. La quantité totale de protéines en présence est également mesurée par le test de Bradford.For each sample tested, the amount of collagen present in the cell matrix and in the culture medium is determined after 48 h of culture, using Sirius red dye (Direct Red 80), which has a particular affinity for the triple structure. helix (Gly-XY) n of native collagen. The total amount of protein present is also measured by the Bradford test.
A cet effet, après 48 h de culture, le milieu de culture est prélevé et la couche de cellules est rincée avec 500 µl de cocktail inhibiteur de protéase. La couche de cellules est ensuite récupérée par grattage dans 500 µl de cocktail inhibiteur de protéase, puis les puits de culture sont rincés avec 500 µl du cocktail inhibiteur de protéase. Les deux volumes, qui constituent la matrice extracellulaire, sont rassemblés et traités par ultrasons pendant 40 s.For this purpose, after 48 h of culture, the culture medium is removed and the cell layer is rinsed with 500 μl of protease inhibitor cocktail. The cell layer is then recovered by scraping in 500 μl of protease inhibitor cocktail, then the culture wells are rinsed with 500 μl of the protease inhibitor cocktail. The two volumes, which constitute the extracellular matrix, are combined and treated by ultrasound for 40 s.
Le collagène est complexé avec le colorant rouge Sirius. Après centrifugation et lavage à l'acide chlorhydrique 0,1 M, le culot est solubilisé dans une solution d'hydroxyde de sodium à 0,5 M. L'absorbance du complexe colorant - collagène est mesurée à 540 nm. Une gamme d'étalonnage est établie entre 0 et 50 µg par tube de collagène.Collagen is complexed with the red dye Sirius. After centrifugation and washing with 0.1 M hydrochloric acid, the pellet is dissolved in a 0.5 M sodium hydroxide solution. The absorbance of the dye-collagen complex is measured at 540 nm. A calibration range is established between 0 and 50 µg per collagen tube.
La quantité totale de protéines en présence est également mesurée par le test de Bradford, selon le protocole décrit dans la publication de
Pour chaque échantillon, il est calculé le rapport en poids de collagène / protéines mesurées par le test de Bradford (dans la matrice cellulaire et dans le milieu de culture), ainsi que le % d'augmentation de la production de collagène par les cellules, par rapport au contrôle négatif.For each sample, the weight ratio of collagen / proteins measured by the Bradford test (in the cell matrix and in the culture medium) is calculated, as well as the% increase in the production of collagen by the cells, compared to the negative control.
Les résultats obtenus sont montrés dans le tableau 1 ci-après.
La
Il ressort clairement des résultats obtenus que l'extrait fermenté de feuilles de Viola alba subsp. dehnhardtii conforme à l'invention augmente de manière significative la production de collagène par les fibroblastes humains, et ce dès la concentration de 1000 µg/ml dans le milieu de culture cellulaire.It is clear from the results obtained that the fermented extract of leaves of Viola alba subsp. dehnhardtii according to the invention significantly increases the production of collagen by human fibroblasts, from the concentration of 1000 μg / ml in the cell culture medium.
Ces résultats démontrent la performance de l'extrait fermenté selon l'invention pour lutter contre le vieillissement cutané.These results demonstrate the performance of the fermented extract according to the invention for combating skin aging.
L'extrait de feuilles de Viola alba subsp. dehnhardtii fermenté obtenu à l'exemple A/ est testé pour sa capacité à lutter contre les biofilms de Propionibacterium acnes et contre les biofilms de Staphylococcus epidermitis. The leaf extract of Viola alba subsp. fermented dehnhardtii obtained in Example A / is tested for its capacity to fight against biofilms of Propionibacterium acnes and against biofilms of Staphylococcus epidermitis.
Le but de cette étude est de déterminer si la capacité de ces bactéries à établir un biofilm, impliqué dans l'acné, peut être freinée, et la maturation de ce biofilm bloquée, par l'extrait fermenté selon l'invention. A cet effet, il est utilisé la méthode du Biofilm Ring Test® de la société Biofilm Control®. Cette méthode permet de déterminer un indice, appelé BFI (pour l'anglais BioFilm Index), qui est inversement proportionnel au niveau de production de biofilm (
Dans ces expériences, le pourcentage de présence du biofilm est déterminé initialement (à 0 h) et après respectivement 2h, 4h, 6h et 24h d'incubation des bactéries avec l'extrait selon l'invention.In these experiments, the percentage of presence of the biofilm is determined initially (at 0 h) and after respectively 2 h, 4 h, 6 h and 24 h of incubation of the bacteria with the extract according to the invention.
Les organismes utilisés dans cette étude sont Propionibacterium acnes KPA 171202 et Staphylococcus epidermidis ATCC 12228.The organisms used in this study are Propionibacterium acnes KPA 171202 and Staphylococcus epidermidis ATCC 12228.
Les protocoles mis en oeuvre sont les suivants.The protocols used are as follows.
Concernant Propionibacterium acnes, un aliquot liquide de bactéries est préparé selon la méthode de Hayes et Markovic légèrement modifiée (
Des cellules de Staphylococcus epidermidis sont incubées dans du bouillon trypticase soja (TSB) pendant 24h à 37 °C en conditions aérobies, puis le milieu est ajusté pour obtenir environ 1,0×108 UFC/ml. Staphylococcus epidermidis cells are incubated in trypticase soy broth (TSB) for 24 h at 37 ° C. under aerobic conditions, then the medium is adjusted to obtain approximately 1.0 × 10 8 CFU / ml.
Les compositions suivantes sont préparées :
Témoin : des éprouvettes de 10 ml contenant 3 ml du bouillon de glucose de levure nutritif (NYG) pour Propionibacterium acnes, ou 3 ml du bouillon de nutriments pour Staphylococcus epidermidis, ont été stérilisées à l'autoclave pendant 12h à 150 °C. Le milieu dans chaque éprouvette a été refroidi puis ensemencé avec 50 µl de la suspension bactérienne de Propionibacterium acnes ou de Staphylococcus epidermidis contenant 1x108 cellules/ml.The following compositions are prepared:
Control: 10 ml test tubes containing 3 ml of nutritive yeast glucose broth (NYG) for Propionibacterium acnes, or 3 ml of nutrient broth for Staphylococcus epidermidis, were autoclaved for 12 h at 150 ° C. The medium in each test tube was cooled and then inoculated with 50 μl of the bacterial suspension of Propionibacterium acnes or of Staphylococcus epidermidis containing 1x10 8 cells / ml.
Compositions à base d'extrait selon l'invention : l'extrait selon l'invention est ajouté, respectivement à 2 % v/v (composition S2%) et à 4 % v/v (composition S4%), dans certaines des éprouvettes ci-dessus.Compositions based on extract according to the invention: the extract according to the invention is added, respectively at 2% v / v (composition S2%) and at 4% v / v (composition S4%), in some of the test tubes above.
Le principe de la méthode Biofilm Ring Test® est décrit par
La
Comme on peut l'observer, concernant Propionibacterium acnes, à 0h tous les échantillons montrent une absence de biofilm (anneau central bien visible sur les photographies) ; à partir de 2h d'incubation, le témoin produit du biofilm en quantité et ce jusqu'à 24h d'incubation (l'anneau central n'est plus visible, témoignant du fait que les particules ont été immobilisées dans le biofilm formé). Pour les échantillons contenant l'extrait selon l'invention (S2% et S4%) on observe une absence de biofilm à toutes les durées d'incubation testées.As we can observe, concerning Propionibacterium acnes, at 0h all the samples show an absence of biofilm (central ring clearly visible in the photographs); from 2 hours of incubation, the control produces biofilm in quantity and this up to 24 hours of incubation (the central ring is no longer visible, testifying to the fact that the particles have been immobilized in the biofilm formed). For the samples containing the extract according to the invention (S2% and S4%), an absence of biofilm is observed at all the incubation times tested.
Concernant Staphylococcus epidermitis, de 0h à 4h tous les échantillons montrent une absence de biofilm ; à partir de 6h d'incubation le témoin produit du biofilm en quantité, et ce jusqu'à 24h. Pour les échantillons contenant l'extrait selon l'invention (S2% et S4%) on observe l'absence de biofilm à toutes les durées d'incubation testées.Concerning Staphylococcus epidermitis, from 0h to 4h all the samples show an absence of biofilm; from 6 hours of incubation the control produces biofilm in quantity, and this up to 24 hours. For the samples containing the extract according to the invention (S2% and S4%), the absence of biofilm at all incubation times tested.
Pour tous les échantillons, le pourcentage de présence de biofilm après 24h d'incubation est calculé. Les résultats sont montrés sur la
Comme on peut l'observer, le témoin montre que Propionibacterium acnes est biofilmogène à 100%, c'est-à-dire que le quorum sensing est maximum et produit du biofilm. L'échantillon selon l'invention S2% montre une diminution de la formation de biofilm de 55%, donc de plus de la moitié par rapport au témoin. L'échantillon selon l'invention S4% montre une diminution de la formation de biofilm de 85% c'est-à-dire que le quorum sensing n'a pas pu développer la maturation du biofilm.As can be observed, the witness shows that Propionibacterium acnes is 100% biofilmogenic, that is to say that the quorum sensing is maximum and produces biofilm. The sample according to the invention S2% shows a reduction in biofilm formation by 55%, therefore by more than half compared to the control. The sample according to the invention S4% shows a reduction in the formation of biofilm by 85%, that is to say that the quorum sensing could not develop the maturation of the biofilm.
Concernant Staphylococcus epidermitis, là encore le témoin montre que Staphylococcus epidermitis est biofilmogène à 100%, c'est-à-dire que le quorum sensing est maximum et produit du biofilm. L'échantillon selon l'invention S2% montre une diminution de la formation de biofilm de 46% par rapport au témoin. L'échantillon selon l'invention S4% montre une diminution de la formation de biofilm de 72%, c'est-à-dire que le quorum sensing n'a pas pu développer la maturation du biofilm.Concerning Staphylococcus epidermitis, here again the witness shows that Staphylococcus epidermitis is 100% biofilmogenic, that is to say that the quorum sensing is maximum and produces biofilm. The sample according to the invention S2% shows a reduction in the formation of biofilm by 46% compared to the control. The sample according to the invention S4% shows a reduction in biofilm formation of 72%, that is to say that the quorum sensing could not develop the maturation of the biofilm.
L'ensemble de ces résultats démontre bien l'efficacité anti-biofilm de l'extrait fermenté selon l'invention sur les deux souches de bactéries testées, qui sont associées aux troubles de l'acné. En empêchant la production de biofilm, l'extrait selon l'invention prévient la formation de bactéries sessiles, et tant Propionibacterium acnes que Staphylococcus epidermitis restent en symbiose avec les kératinocytes de la peau et conservent leur activité commensale de protection de la barrière cutanée.All of these results clearly demonstrate the anti-biofilm efficacy of the fermented extract according to the invention on the two strains of bacteria tested, which are associated with acne disorders. By preventing the production of biofilm, the extract according to the invention prevents the formation of sessile bacteria, and both Propionibacterium acnes and Staphylococcus epidermitis remain in symbiosis with the keratinocytes of the skin and retain their commensal activity for protecting the skin barrier.
Claims (12)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1857951A FR3085270B1 (en) | 2018-09-05 | 2018-09-05 | FERMENT VIOLET EXTRACT, PROCESS FOR OBTAINING SUCH EXTRACT AND USE IN COSMETICS |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3620212A1 true EP3620212A1 (en) | 2020-03-11 |
EP3620212B1 EP3620212B1 (en) | 2021-03-24 |
Family
ID=65201279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19195311.6A Active EP3620212B1 (en) | 2018-09-05 | 2019-09-04 | Fermented violet extract, method for obtaining such an extract and use in cosmetics |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3620212B1 (en) |
FR (1) | FR3085270B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3132436A1 (en) * | 2022-02-08 | 2023-08-11 | Isp Investments Llc | METHOD FOR OBTAINING PLANT EXTRACTS COMPRISING A SELF-FERMENTATION STEP, COMPOSITIONS COMPRISING SUCH EXTRACTS AND THEIR COSMETIC USES |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050089499A1 (en) * | 2002-01-15 | 2005-04-28 | Philippe Moussou | Active substances for use in cosmetic and/or pharmaceutical products, obtainable from the fermentation of plant components and/or plant extracts |
US20150224158A1 (en) | 2006-06-16 | 2015-08-13 | Kefiplant Inc. | Fermented plant extracts, methods of production and uses |
-
2018
- 2018-09-05 FR FR1857951A patent/FR3085270B1/en not_active Expired - Fee Related
-
2019
- 2019-09-04 EP EP19195311.6A patent/EP3620212B1/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050089499A1 (en) * | 2002-01-15 | 2005-04-28 | Philippe Moussou | Active substances for use in cosmetic and/or pharmaceutical products, obtainable from the fermentation of plant components and/or plant extracts |
US20150224158A1 (en) | 2006-06-16 | 2015-08-13 | Kefiplant Inc. | Fermented plant extracts, methods of production and uses |
Non-Patent Citations (8)
Title |
---|
BRADFORD ET AL., ANAL. BIOCHEM., vol. 72, 1976, pages 248 - 54 |
BURKARTBURKART, INT. J. DERMATOL., vol. 42, 2003, pages 925 - 927 |
CHAVANT ET AL., J MED MICROBIOL, vol. 60, 1997, pages 300 - 306 |
DAGNELIE ET AL., ANNALES DE DERMATOLOGIE ET DE VÉNÉRÉOLOGIE, vol. 145, no. 12, 2018, pages 123 |
DATABASE GNPD [online] MINTEL; 1 December 2017 (2017-12-01), UNKNOWN: "340 Serum, Maria Galland", XP002790986, Database accession no. 5339243 * |
HAYESMARKOVIC, FOOD CHEM TOXICOL., vol. 40, 2002, pages 535 - 543 |
KIM KYOUNG-SOOK ET AL: "Purification and structure determination of gelatinase and collagenase inhibitors from Viola patrinii fermentation extracts", IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, vol. 32, no. 4, December 2010 (2010-12-01), pages 614 - 616, XP009512897, ISSN: 0892-3973 * |
NAOHIRO OSHIMA ET AL: "Collagenase inhibitors from", JOURNAL OF NATURAL MEDICINES, SPRINGER-VERLAG, TO, vol. 67, no. 1, 13 April 2012 (2012-04-13), pages 240 - 245, XP035150988, ISSN: 1861-0293, DOI: 10.1007/S11418-012-0665-8 * |
Also Published As
Publication number | Publication date |
---|---|
FR3085270B1 (en) | 2020-08-14 |
FR3085270A1 (en) | 2020-03-06 |
EP3620212B1 (en) | 2021-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2395283C (en) | Use of an extract of at least one plant of genus vaccinium as antiglycation agent | |
EP3512606B1 (en) | Cosmetic and/or nutraceutic or dermatological use of a yeast extract | |
EP2986347B1 (en) | Cosmetic applications of lactobacillus pentosus | |
Yu et al. | Saussurea lappa inhibits the growth, acid production, adhesion, and water-insoluble glucan synthesis of Streptococcus mutans | |
FR2915897A1 (en) | COSMETIC COMPOSITION COMPRISING AN ADENIUM OBESUM EXTRACT, ITS USE AND A METHOD OF COSMETIC CARE COMPRISING THE APPLICATION | |
KR102004322B1 (en) | Cosmetic composition containing botanical extract complex | |
JP2009029788A (en) | Skin care composition for external use containing seawater-derived yeast culture | |
EP3620212B1 (en) | Fermented violet extract, method for obtaining such an extract and use in cosmetics | |
WO2012007670A2 (en) | Cosmetic or dermatological composition and use thereof for caring for the skin of young men | |
WO2022018392A1 (en) | Polysaccharide-rich bombax costatum flower extract | |
KR102377447B1 (en) | Suaeda japonica and scoria Complex fermentation product having increased polyphenol content, preparing method the same and cosmetic composition by using the same | |
WO2022112725A2 (en) | Fermented extract of ushant honey | |
CN116370364A (en) | Rosemary ferment, external composition containing the same and having oil control and red dispelling effects and application thereof | |
FR2931675A1 (en) | Cosmetic or dermatological composition, useful e.g. for cosmetic treatment e.g. to tighten pores, and inhibit growth of Staphylococcus aureus, comprises rice extract, rice vinegar, matte powder, meadowsweet extract and essential oil | |
KR20180103374A (en) | A cosmetic composition containing Dendropanax morbifera ferment extract as an active ingredient and Functional cosmetics having anti-inflammation and sensitive skin improvement containing the same | |
FR3125715A1 (en) | Composition comprising an antioxidant, a particular fatty acid ester, a lysate of Bifidobacterium species and a yeast extract | |
WO2020065213A1 (en) | Use of an agave extract for enhancing the barrier function of the skin, scalp and/or mucusa and modulating the skin microbiota | |
FR2962330A1 (en) | Cosmetic use of an extract of Musa sapientum to stimulate the production of collagen type I to fight against skin aging and to prevent and/or limit the appearance of signs of skin aging | |
WO2017113263A1 (en) | Novel use of gluconacetobacter xylinus fermentation broth as cosmetic composition | |
EP2367525B1 (en) | Composition containing saponins | |
TWI606845B (en) | Microbial fermentation products of gluconacetobacter xylinus for use in cosmetic composition | |
FR3132436A1 (en) | METHOD FOR OBTAINING PLANT EXTRACTS COMPRISING A SELF-FERMENTATION STEP, COMPOSITIONS COMPRISING SUCH EXTRACTS AND THEIR COSMETIC USES | |
WO2022144513A1 (en) | Fermented extract of longoza seeds | |
TW202313087A (en) | Prunus salicinaferment, manufacturing method thereof, and uses thereof | |
WO2023156745A1 (en) | Composition comprising a myrtle extract and a tripterygium wilfordii extract for controlling acne of non-lesional areas of acneic skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200727 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602019003410 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61P0017020000 Ipc: A61K0036860000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61Q 19/00 20060101ALI20201119BHEP Ipc: A61K 36/86 20060101AFI20201119BHEP Ipc: A61P 17/02 20060101ALI20201119BHEP Ipc: A61K 8/9789 20170101ALI20201119BHEP Ipc: A61P 17/10 20060101ALI20201119BHEP |
|
INTG | Intention to grant announced |
Effective date: 20201209 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602019003410 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1373790 Country of ref document: AT Kind code of ref document: T Effective date: 20210415 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210624 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210624 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210625 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210324 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1373790 Country of ref document: AT Kind code of ref document: T Effective date: 20210324 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210726 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210724 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602019003410 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
26N | No opposition filed |
Effective date: 20220104 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602019003410 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210724 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210904 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210904 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220401 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220930 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20190904 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230904 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230904 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230904 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240926 Year of fee payment: 6 |